Formulation of Therapeutic Proteins: Strategies for Developing Oral Protein Formulations

Patil, Saurabh; Narvekar, Aditya; Puranik, Amita; Jain, Ratnesh; Dandekar, Prajakta

doi:10.1002/9783527812172.ch12

Cited by 6 publications

(3 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral administration of therapeutics remains the most straightforward approach for maximizing patient compliance. Barriers to oral protein delivery include the gastrointestinal environment (acidic and proteolytic enzymes) and low permeability of protein drugs across biological membranes in the intestines . Two studies have investigated MOFs as a solution for oral delivery of protein therapeutics, specifically insulin.…”

Section: Case Studiesmentioning

confidence: 99%

Metal–Organic Frameworks for Drug Delivery: A Design Perspective

Lawson

Walton

Chan

2021

ACS Appl. Mater. Interfaces

566

351

View full text Add to dashboard Cite

The use of metal–organic frameworks (MOFs) in biomedical applications has greatly expanded over the past decade due to the precision tunability, high surface areas, and high loading capacities of MOFs. Specifically, MOFs are being explored for a wide variety of drug delivery applications. Initially, MOFs were used for delivery of small-molecule pharmaceuticals; however, more recent work has focused on macromolecular cargos, such as proteins and nucleic acids. Here, we review the historical application of MOFs for drug delivery, with a specific focus on the available options for designing MOFs for specific drug delivery applications. These options include choices of MOF structure, synthetic method, and drug loading. Further considerations include tuning, modifications, biocompatibility, cellular targeting, and uptake. Altogether, this Review aims to guide MOF design for novel biomedical applications.

show abstract

Section: Case Studiesmentioning

confidence: 99%

Metal–Organic Frameworks for Drug Delivery: A Design Perspective

Lawson

Walton

Chan

2021

ACS Appl. Mater. Interfaces

566

351

View full text Add to dashboard Cite

show abstract

“…The clinical development of proteins is faster than that of small-molecules or peptides [155], although their chemical-physical properties put wide restrictions on transdermal delivery [156]. Particularly, proteins are subject to degradation in aqueous environments, undergoing aggregation, denaturation, or precipitation mechanisms [157,158].…”

Section: Discussionmentioning

confidence: 99%

Progress in Microneedle-Mediated Protein Delivery

Jamaledin

Natale

Onesto

et al. 2020

JCM

View full text Add to dashboard Cite

The growing demand for patient-compliance therapies in recent years has led to the development of transdermal drug delivery, which possesses several advantages compared with conventional methods. Delivering protein through the skin by transdermal patches is extremely difficult due to the presence of the stratum corneum which restricts the application to lipophilic drugs with relatively low molecular weight. To overcome these limitations, microneedle (MN) patches, consisting of micro/miniature-sized needles, are a promising tool to perforate the stratum corneum and to release drugs and proteins into the dermis following a non-invasive route. This review investigates the fabrication methods, protein delivery, and translational considerations for the industrial scaling-up of polymeric MNs for dermal protein delivery.

show abstract

“…Some proteins are cell impermeable or do not have cell membrane receptors to facilitate the cell entry, which are specific to certain cell types. Nonetheless, therapeutic proteins are sought because unlike the small-molecule drugs, they can be very selective for specific disease hallmarks [ 13 ]. Initially, proteins were isolated from humans, animals, and plants.…”

Section: Introductionmentioning

confidence: 99%

Cytochrome c: Using Biological Insight toward Engineering an Optimized Anticancer Biodrug

et al. 2021

View full text Add to dashboard Cite

The heme protein cytochrome c (Cyt c) plays pivotal roles in cellular life and death processes. In the respiratory chain of mitochondria, it serves as an electron transfer protein, contributing to the proliferation of healthy cells. In the cell cytoplasm, it activates intrinsic apoptosis to terminate damaged cells. Insight into these mechanisms and the associated physicochemical properties and biomolecular interactions of Cyt c informs on the anticancer therapeutic potential of the protein, especially in its ability to subvert the current limitations of small molecule-based chemotherapy. In this review, we explore the development of Cyt c as an anticancer drug by identifying cancer types that would be receptive to the cytotoxicity of the protein and factors that can be finetuned to enhance its apoptotic potency. To this end, some information is obtained by characterizing known drugs that operate, in part, by triggering Cyt c induced apoptosis. The application of different smart drug delivery systems is surveyed to highlight important features for maintaining Cyt c stability and activity and improving its specificity for cancer cells and high drug payload release while recognizing the continuing limitations. This work serves to elucidate on the optimization of the strategies to translate Cyt c to the clinical market.

show abstract

Formulation of Therapeutic Proteins: Strategies for Developing Oral Protein Formulations

Cited by 6 publications

References 145 publications

Metal–Organic Frameworks for Drug Delivery: A Design Perspective

Metal–Organic Frameworks for Drug Delivery: A Design Perspective

Progress in Microneedle-Mediated Protein Delivery

Cytochrome c: Using Biological Insight toward Engineering an Optimized Anticancer Biodrug

Contact Info

Product

Resources

About